NCT03563573 is a Phase 1, PHASE2 clinical trial of Potassium Gluconate Oral Capsule in ADHD, sponsored by AlkaliDx, Inc..

Who is sponsoring NCT03563573?

NCT03563573 is sponsored by AlkaliDx, Inc..

What drugs are being tested in NCT03563573?

Interventions in NCT03563573: Potassium Gluconate Oral Capsule, Placebo oral capsule.

Is NCT03563573 still recruiting?

NCT03563573 is currently status unknown. Last updated 20 June 2018.

Last reviewed 2018-06-20 · How we verify

NCT03563573

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Single-dose Potassium Supplementation in Patients With ADHD for Whom the Anesthetic Lidocaine is Ineffective

Status unknown Phase 1, PHASE2 Last updated 20 June 2018

What this trial tests

Phase 1, PHASE2 trial testing Potassium Gluconate Oral Capsule in ADHD in 100 participants. Status unknown.

Timeline

1 July 2018

Primary endpoint
4 November 2018

31 December 2018

Quick facts

Lead sponsor	AlkaliDx, Inc.
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	100
Start date	1 July 2018
Primary completion	4 November 2018
Estimated completion	31 December 2018
Sites	1 location across United States

Drugs / interventions tested

Potassium Gluconate Oral Capsule
Placebo oral capsule

Conditions studied

ADHD — all drugs for ADHD →

Sponsor

AlkaliDx, Inc.

Who can join

Adults 13 to 49, any sex, with ADHD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Randomized, controlled, double-blind trial of the effect of a single dose of potassium on ADHD symptoms as measured by changes in measures of symptoms of ADHD correlated with the results of their Lidocaine Effectiveness Test.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for ADHD

Currently open trials in the same condition.

NCT07314333 — A Trial to Assess How Centanafadine Interacts With Stimulants in the Body · Phase 1 · recruiting
NCT07262853 — Dual Executive Function Training Package · NA · recruiting
NCT07291453 — Loving Habits: A Feasibility Study of a Support Program for Building New Parent-child Behavioral Habits · NA · recruiting
NCT07281092 — Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) · NA · recruiting
NCT07219810 — Accelerated iTBS Targeting of Working Memory Versus Inhibitory Control in Adolescent ADHD · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03563573 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AlkaliDx, Inc.
Last refreshed: 20 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03563573.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing